Comment
Urgent need for pragmatic trial platforms in severe asthma

https://doi.org/10.1016/S2213-2600(18)30291-1Get rights and content

First page preview

First page preview
Click to open first page preview

References (11)

There are more references available in the full text version of this article.

Cited by (17)

  • The emergence of new biologics for severe asthma

    2019, Current Opinion in Pharmacology
    Citation Excerpt :

    These clinical characteristics are now considered typical of the severe eosinophilic asthma phenotype [39]. Currently, there are no head-to-head studies comparing the efficacy of the 3 anti-IL-5 biologics yet, but one trial comparing omalizumab with mepolizumab in severe combined allergic and eosinophilic asthma is underway (PREDICTUMAB) [40]. Nonetheless, there are some differences between these biologics which may be relevant to clinicians.

  • Biologics for paediatric severe asthma: trick or TREAT?

    2019, The Lancet Respiratory Medicine
  • Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?

    2023, American Journal of Respiratory and Critical Care Medicine
  • Asthma and Tobacco Smoking

    2022, Journal of Personalized Medicine
View all citing articles on Scopus
View full text